Collegium Appoints Nancy S. Lurker to its Board of Directors

Core Viewpoint - Collegium Pharmaceutical, Inc. has appointed Nancy S. Lurker to its Board of Directors, effective February 4, 2025, which is expected to enhance the company's strategic growth and commercial capabilities [1][2]. Company Overview - Collegium Pharmaceutical is focused on building a diversified biopharmaceutical company aimed at improving the lives of individuals with serious medical conditions [5]. - The company has a strong portfolio in responsible pain management medications and has recently expanded into the neuropsychiatry market with the acquisition of Jornay PM, a treatment for ADHD [5]. Leadership and Expertise - Nancy S. Lurker brings extensive experience in commercial growth and strategic acquisitions, having previously served as President and CEO of EyePoint Pharmaceuticals and held leadership roles at PDI, Inc. and Novartis Pharmaceuticals [2][3]. - Lurker's appointment is seen as pivotal for Collegium as it enters a new growth phase [2]. Board and Advisory Roles - In addition to her role at Collegium, Lurker serves on the boards of Alkermes plc and Altasciences, LLC, and is involved with advisory boards for Novo Holdings and Stanford Medicine [3]. - Her previous board positions include notable companies such as Cancer Treatment Centers of America and Mallinckrodt Pharmaceuticals [3]. Educational Background - Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville [4].